News | December 26, 2012

FSS Introduces Stent Delivery Technology for Reconstrainable FlexStent Femoropopliteal System

December 26, 2012 — Flexible Stenting Solutions Inc. (FSS) announced it gained CE mark in the European Union for its 6 French Reconstrainable FlexStent Femoropopliteal self-expanding stent system. FSS is a developer of next-generation peripheral, neurovascular and biliary stents. This new device combines advanced FlexStent technology with unique reconstrainable stent delivery technology.

Reconstrainability enables the physician to fully recapture, then reposition, a partially deployed stent. Based on ongoing market research and physician feedback, FSS believes reconstrainability will be a powerful tool for optimizing stent placement in challenging vascular anatomies, thereby enhancing overall patient safety. The Reconstrainable FlexStent Femoropopliteal self-expanding stent system is indicated for the treatment of symptomatic atherosclerotic disease of the femoropopliteal arteries. Stent and system sizes include stent diameters of 5, 6, 7 and 8 mm in lengths of 30 to 200 mm, with delivery system lengths of 80 cm and 120 cm, as originally CE mark authorized with the standard delivery system.

FSS intends to apply the novel reconstrainable delivery technology across its platform of current and future stent products. With the easy-to-use reconstrainable delivery system, the complete FlexStent family of stents can be delivered with the same simplicity and low force demonstrated by the standard delivery system. Recapture and secondary deployment of the stent in the reconstrainable system are both accomplished with equal ease and simplicity.

For more information: www.flexiblestent.com

Related Content

he 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent showed low rates of revascularization and compared very favorably to current standards of care.  The results were presented by Professor Thomas Zeller, M.D., University Heart Centre Freiburg, Bad Krozingen, Germany at the CX 2020 Live conference.   
News | Peripheral Artery Disease (PAD) | June 16, 2020
June 16, 2020 — The 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent
The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

News | Peripheral Artery Disease (PAD) | March 28, 2020
March 28, 2020 — People with symptomatic...
News | Peripheral Artery Disease (PAD) | November 14, 2019
November 7, 2019 — Ultrasoundplasty before angioplasty for below-the-knee lesions (BTK) lesions may improve clinical
News | Peripheral Artery Disease (PAD) | November 14, 2019
November 14, 2019 — There were positive results in the TANGO Trial is a phase 2, dose escalation, double-blinded tria
The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot.  #VIVA #VIVA19 #VIVA2019

The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot. 

News | Peripheral Artery Disease (PAD) | November 14, 2019
November 14, 2019 — Results were positive for the multicenter PROMISE I Trial represents the first human use in the U
Eluvia and Ranger PAD devices from Boston Scientific. #VIVA19 #VIVA2019 #VIVA
News | Peripheral Artery Disease (PAD) | November 06, 2019
November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-elutin
FDA Panel Recommends Continued Use of Paclitaxel-coated Peripheral Devices
Feature | Peripheral Artery Disease (PAD) | August 28, 2019 | Jeff Zagoudis, Associate Editor
The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the safety of paclitaxel-...
New Report Says Concept Medical Positioned to Disrupt Peripheral Market
News | Peripheral Artery Disease (PAD) | August 27, 2019
Concept Medical was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA)...
PAD Intervention Patients on Statins Less Likely to Face Amputation
News | Peripheral Artery Disease (PAD) | August 23, 2019
Patients with peripheral artery disease (PAD) were significantly less likely to face amputation after surgical...
Concept Medical Granted FDA Breakthrough Device Designation for MagicTouch PTA Sirolimus Coated Balloon
News | Peripheral Artery Disease (PAD) | August 14, 2019
Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and Drug...